Publication | Open Access

Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein

Tumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint InhibitorAntigen ProcessingT Cell ImmunityCellular Immune ResponseImmunotherapyMedicineCell BiologyAntitumor Activities